Combination of Lenalidomide and Obinutuzumab (GA101) in patients with Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
The goal of this research study is to learn if the combination of lenalidomide and obinutuzumab can help to control CLL or SLL. The safety of this drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 03/31/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: